Reviewer's report

Title: A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer

Version: 1 Date: 12 June 2007

Reviewer: William Berry

Reviewer's report:

General: I find this to be a well written article on this research trial. The rationale for the trial, design, statistical methods, results, and conclusions are well presented. The conclusions are justified.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached) None

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct) None

Discretionary Revisions (which the author can choose to ignore) None

What next?: Accept without revision

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests.